Wehbe Fabien, Adams Levi, Babadoudou Jordan, Yuen Samantha, Kim Yoon-Seong, Tanaka Yoshiaki
Maisonneuve-Rosemont Hospital Research Center (CRHMR), Department of Medicine, University of Montreal, Quebec H1T 2M4, Canada.
RWJMS Institute for Neurological Therapeutics, Rutgers-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA.
Genome Res. 2025 Jan 22;35(1):135-146. doi: 10.1101/gr.278812.123.
Application of single-cell/nucleus genomic sequencing to patient-derived tissues offers potential solutions to delineate disease mechanisms in humans. However, individual cells in patient-derived tissues are in different pathological stages, and hence, such cellular variability impedes subsequent differential gene expression analyses. To overcome such a heterogeneity issue, we present a novel deep learning approach, scIDST, that infers disease progression levels of individual cells with weak supervision framework. The disease progression-inferred cells display significant differential expression of disease-relevant genes, which cannot be detected by comparative analysis between patients and healthy donors. In addition, we demonstrate that pretrained models by scIDST are applicable to multiple independent data resources and are advantageous to infer cells related to certain disease risks and comorbidities. Taken together, scIDST offers a new strategy of single-cell sequencing analysis to identify bona fide disease-associated molecular features.
将单细胞/细胞核基因组测序应用于患者来源的组织为阐明人类疾病机制提供了潜在的解决方案。然而,患者来源组织中的单个细胞处于不同的病理阶段,因此,这种细胞变异性阻碍了后续的差异基因表达分析。为了克服这种异质性问题,我们提出了一种新的深度学习方法scIDST,它通过弱监督框架推断单个细胞的疾病进展水平。推断出疾病进展的细胞显示出与疾病相关基因的显著差异表达,这是患者与健康供体之间的比较分析无法检测到的。此外,我们证明scIDST预训练模型适用于多个独立数据资源,有利于推断与某些疾病风险和合并症相关的细胞。综上所述,scIDST为单细胞测序分析提供了一种新策略,以识别真正的疾病相关分子特征。